More importantly, aberrant CD123 expression was found in AML stem cells (LSCs) (CD34+/CD38-cells) but not in normal bone marrow CD34+/CD38− cells, making it an attractive therapeutic target for AML (14). Here, CD34 is linked to acute myeloid leukemia.